Implandata Ophthalmic Products GmbH (IOP), a Hannover, Germany-based specialist in diagnostic systems for monitoring chronic eye diseases such as glaucoma, has completed a €1.6m second closing of its €3.0m Series A financing.
The company intends to use the capital to run a CE trial to achieve early market access for its new diagnostic system.
Led by Max Ostermeier, Managing Director, IOP has developed a new diagnostic system that can (on demand and repeatedly) measure the intraocular pressure of an individual glaucoma patient. It enables early diagnosis of the disease as well as monitoring the progression and therapy, thereby protecting patients against blindness.
In the future, the system will be embedded in a telemedical diagnostic platform which will allow a better guidance of these patients by connecting them with doctors and thereby improving/increasing compliance.
It consists of a minimally invasive micro-sensor which is implanted into the eye and a handheld unit. Patients can thereby easily measure their intraocular pressure at home under an individual protocol discussed with doctors. IOP’s first product – an intraocular sensor – is currently in a CE approval trial and data is expected within the next 18 months.
The company held the first closing in December 2011 with €1.4m (read here).